Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Medical Oncology
•
Ovarian Cancer
Do you offer PARP inhibitor maintenance therapy to stage IC high grade serous ovarian cancer patients?
Related Questions
What are your top takeaways in Gyn Cancers from ESMO 2024?
How would you approach a patient who is unable to undergo the recommended ophthalmologic examinations during treatment with mirvetuximab soravtansine?
In a patient with stage IVB HER2 3+ high-grade serous endometrial cancer who had disease confined to a polyp and "microscopic" omental metastases, how long would you continue maintenance trastuzumab after chemotherapy?
Would you add olaparib to maintenance immunotherapy for a patient with recurrent MMR-proficient, HER2-negative serous endometrial carcinoma?
Does being on maintenance pembrolizumab change how you manage patients with partial metabolic response on PET/CT 3 months after chemoradiation for cervical cancer?
How do you counsel patients about prognosis with FIGO 2018 IIIC cervix cancer managed in the new era of chemoradiation plus immunotherapy?
What are your top takeaways from SGO 2025?
Do you believe the collective data support neoadjuvant chemotherapy or primary debulking surgery for patients with advanced ovarian cancer?
What screening tools or signs do you use to predict if a cancer patient is near end-of-life?
Would you use a GI regimen (FOLFOX) or a GYN regimen (Carboplatin/Paclitaxel +/- immuno) for a 71yo women with ascites, a large pelvic mass arising from the uterus (on CT), and peritoneal implants that are CDX2 positive, PAX 8 / WT-1 negative, p53 wild type, intestinal type?
